Xarelto may be alternative for cancer patients with VTE

Share this content:

Patients with cancer who have had venous thromboembolism may have lower risk of bleeding with XARELTO® (rivaroxaban) , a study in Lancet Haematology suggests

Results were presented at a European Society for Medical Oncology meeting last weekend, and were based on Phase 3 data for looking at the anticoagulant in cancer patients.

XARELTO® was the first oral anticoagulant approved to treat VTE events, including deep vein thrombosis (DVT) and pulmonary embolism, and to reduce the risk of these events occurring again, without the need for routine blood monitoring. 


Next Article in Products